Scan brief descriptions of cost-effectiveness analyses conducted by our center community and our decision science colleagues across the globe.

Image of Nicole Campos.

Scaling Cancer Prevention

This analysis used decision analytic modeling to estimate the health impact, costs, and cost-effectiveness of scaling-up HPV vaccination and cervical cancer screening in 50 low- and lower-middle-income countries. Read the HPV article.

Image of Stephane Verguet.

Cost Effectiveness and Equity

An "equity impact plane," considers trade-offs between improving total health, the objective underpinning conventional CEA, and equity objectives, such as reducing social inequality in health or prioritizing the severely ill. Read the equity article.

Image of Stephen Resch Filming in the GHELI Studio.

Cost-Effectiveness Thresholds

Interventions that impose costs per DALY averted less than 3x and 1x GDP per capita are considered cost-effective and very cost-effective, respectively. This article explores the conceptual foundation and derivation of this threshold.  Read the thresholds article.

Cost-effectiveness and Affordability

Cost-effectiveness acceptability curves summarize the distribution of expected benefits and costs in the context of multivariate uncertainty, but don't distinguish between joint distributions of costs and effects that are correlated but differ in scale. Learn how cost-effectiveness and affordability were both considered for HBV vaccination in the Gambia.

Cervical Cancer Screening in Nicaragua

A Monte Carlo simulation model of the natural history of HPV infection and cervical cancer was empirically calibrated to epidemiological data in Nicaragua. After integrating country-specific data on screening costs and test performance, the cost-effectiveness of alternative cervical cancer screening strategies was evaluated. About the screening strategy.

Rotavirus versus HPV Vaccination

Immunization policymakers at global and local levels need to establish priorities among new vaccines competing for limited resources. This study provides early insight into how the comparative impact of two new vaccines could be assessed in resource-poor settings with respect to affordability, cost-effectiveness, and distributional equity. Read the vaccine study.